More medications are needed today to
achieve acute improvement in bipolar patients. This may be due
to a higher prevalence of rapid cycling and an earlier age of
onset of bipolar illness. The drugs (monotherapy and combination
therapy) currently available for treatment were reviewed. Dr.
Post shared his strategy for the treatment of rapid cycling
patients.
At the National Institute of Mental Health, discharge data
from the past 30 years (1970 to 2000) indicate that more medications
are needed today to achieve acute improvement in bipolar patients.
The data for the year 2000 shows a higher prevalence of rapid
cycling and an earlier age of onset of illness compared to
the 1970's. For patients with bipolar disorder, this means
that their children may present with initial symptoms 8 to
10 years earlier than the parent. In addition, these children
may experience rapid cycling 2 to 3 times as frequent as the
parent. Dr. Post cited this as one reason bipolar disorder
is currently harder to treat.
Dr. Post reviewed the current treatment choices. He noted
that lamotrigine has antidepressant effects with little switch
liability. In contrast, gabapentin is not an antimanic or
mood stabilizing agent. Topiramate is promising as a mood
stabilizer and has the positive side effect of weight loss.
The atypical antipsychotics are widely used in bipolar illness.
The efficacy of atypical antipsychotics in depression and
long-term prophylaxis has not been adequately studied. These
drugs may be associated with weight gain. Thyroid and other
augmentation strategies such as omega-3 fatty acids are being
used, but additional data are needed to determine the validity
of these treatments.
One Schema for
Treatment of Rapid Cyclers
Combination
Treatment | - |
| Lithium
+ Valproate |
| Schizoaffective,
substance abuse |
| Lithium
+ Carbamazepine |
| Lithium
+ LTG | Adjunctive | - |
| Clonazepam,
Lorazepam or Gabapentin |
| Atypical
antipsychotics |
| condition
Third mood stabilizer |
| Topiramate |
| Naltrexone,
Acamprosate |
| Dihydropyridine
calcium blocker |
| MAOI,
(SNRI + Bupropion) |
|
Lithium, carbamazepine, and valproate are widely recognized
mood stabilizers. Yet, even when they are used with antidepressants,
benzodiazepines, and typical and atypical neuroleptics, there
is a high incidence of insufficient response in bipolar patients.
For example, a recent study demonstrated a low (25%) response
to combination therapy of lithium and valproate in rapid cycling
bipolar illness. In addition, depressed breakthrough days
were approximately 2.5 times more frequent than the number
of days spent in mania. For these reasons, new antidepressant
strategies are needed for the treatment of bipolar disorder.
Dr. Post obtained better responses with combination therapy.
The average number of medications needed for his patients
to be discharged from the National Institute of Mental Health
is currently 4.4.
Dr. Post remarked that this strategy is used in conjunction
with mood charts. Mood charts are carefully prepared by his
patients. Working together, the patient and doctor plan a
treatment of action.
|